Long-term follow-up (median 62.3 months) of the phase 2 GeparX trial in high-risk early breast cancer: neoadjuvant denosumab did not significantly improve invasive disease-free (HR 0.86) or overall survival; distant relapse was lower on multivariate analysis (HR 0.64).
RCT
Link et al. Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)